# Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

> **NCT02483936** · PHASE3 · WITHDRAWN · sponsor: **EMS**

## Conditions studied

- Arterial Hypertension

## Interventions

- **DRUG:** Olmesartan medoxomil 40mg + chlorthalidone 12,5mg
- **DRUG:** Olmesartan medoxomil 40mg + chlorthalidone 25mg
- **DRUG:** Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- **DRUG:** Olmesartan 40mg + Hydrochlorothiazide 25mg

## Key facts

- **NCT ID:** NCT02483936
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2025-06-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided by Sponsor
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483936, "Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02483936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*